118 related articles for article (PubMed ID: 38639528)
1. High MCM6 expression promotes proliferation and correlates with poor prognosis in triple-negative breast cancer.
Zhang H; Lin YD; Zhuang MX; Zhu L; Yu Y; Chen XG; Wang QS; Lin MB
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(7):2906-2922. PubMed ID: 38639528
[TBL] [Abstract][Full Text] [Related]
2. Methylation-dependent MCM6 repression induced by LINC00472 inhibits triple-negative breast cancer metastasis by disturbing the MEK/ERK signaling pathway.
Shao G; Fan X; Zhang P; Liu X; Huang L; Ji S
Aging (Albany NY); 2021 Feb; 13(4):4962-4975. PubMed ID: 33668040
[TBL] [Abstract][Full Text] [Related]
3. MCM6 promotes intrahepatic cholangiocarcinoma progression by upregulating E2F1 and enhancing epithelial-mesenchymal transition.
Gao C; Li J; Zeng F; Wang L; Chen K; Chen D; Hong J; Qu C
Carcinogenesis; 2023 Jun; 44(4):279-290. PubMed ID: 37185675
[TBL] [Abstract][Full Text] [Related]
4. MCM family in HCC: MCM6 indicates adverse tumor features and poor outcomes and promotes S/G2 cell cycle progression.
Liu Z; Li J; Chen J; Shan Q; Dai H; Xie H; Zhou L; Xu X; Zheng S
BMC Cancer; 2018 Feb; 18(1):200. PubMed ID: 29463213
[TBL] [Abstract][Full Text] [Related]
5. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
6. Minichromosome maintenance 6 complex component identified by bioinformatics analysis and experimental validation in esophageal squamous cell carcinoma.
Li X; Ren Z; Xiong C; Geng J; Li Y; Liu C; Ren C; Liu H
Oncol Rep; 2020 Sep; 44(3):987-1002. PubMed ID: 32583000
[TBL] [Abstract][Full Text] [Related]
7. MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer.
Lei Z; Wang P; Jia DQ; Li LL; Wu YP; Yang Y; Pan GQ
Front Biosci (Landmark Ed); 2023 Aug; 28(8):128. PubMed ID: 37664925
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of MCM6 predicts poor survival in patients with glioma.
Cai HQ; Cheng ZJ; Zhang HP; Wang PF; Zhang Y; Hao JJ; Wang MR; Wan JH
Hum Pathol; 2018 Aug; 78():182-187. PubMed ID: 29753008
[TBL] [Abstract][Full Text] [Related]
9. MCM2-7 in Clear Cell Renal Cell Carcinoma: MCM7 Promotes Tumor Cell Proliferation.
Zhang J; Zhang H; Wang Y; Wang Q
Front Oncol; 2021; 11():782755. PubMed ID: 34993142
[TBL] [Abstract][Full Text] [Related]
10. The DNA replication regulator MCM6: An emerging cancer biomarker and target.
Zeng T; Guan Y; Li YK; Wu Q; Tang XJ; Zeng X; Ling H; Zou J
Clin Chim Acta; 2021 Jun; 517():92-98. PubMed ID: 33609557
[TBL] [Abstract][Full Text] [Related]
11. GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer.
Zheng Y; Shi Y; Yu S; Han Y; Kang K; Xu H; Gu H; Sang X; Chen Y; Wang J
Anal Cell Pathol (Amst); 2019; 2019():1038069. PubMed ID: 32082966
[TBL] [Abstract][Full Text] [Related]
12. MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis.
Issac MSM; Yousef E; Tahir MR; Gaboury LA
Neoplasia; 2019 Oct; 21(10):1015-1035. PubMed ID: 31476594
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of Kinase Family 15 Inhibits Cancer Cell Proliferation In vitro and its Clinical Relevance in Triple-Negative Breast Cancer.
Sheng J; Xue X; Jiang K
Curr Mol Med; 2019; 19(2):147-155. PubMed ID: 30854965
[TBL] [Abstract][Full Text] [Related]
14. Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells.
Ling Y; Cao Q; Liu Y; Zhao J; Zhao Y; Li K; Chen Z; Du X; Huo X; Kang H; Chen Z
Breast Cancer; 2021 Mar; 28(2):368-378. PubMed ID: 33047272
[TBL] [Abstract][Full Text] [Related]
15. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
16. MCM6 is a critical transcriptional target of YAP to promote gastric tumorigenesis and serves as a therapeutic target.
Wang Y; Chen H; Liu W; Yan H; Zhang Y; Cheung AHK; Zhang J; Chen B; Liang L; Zhou Z; Wong CC; Wu WKK; Chan MWY; Cheng ASL; Ma BBY; Yu J; Lo KW; To KF; Kang W
Theranostics; 2022; 12(15):6509-6526. PubMed ID: 36185598
[No Abstract] [Full Text] [Related]
17. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
[TBL] [Abstract][Full Text] [Related]
18. A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer.
Zhang J; Zhang M; Tian Q; Yang J
Clin Exp Med; 2023 Nov; 23(7):3867-3881. PubMed ID: 37219794
[TBL] [Abstract][Full Text] [Related]
19. Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.
Hotton J; Agopiantz M; Leroux A; Charra-Brunaud C; Marie B; Busby-Venner H; Morel O; Guéant JL; Vignaud JM; Battaglia-Hsu SF; Gauchotte G
Virchows Arch; 2018 Apr; 472(4):623-633. PubMed ID: 29243125
[TBL] [Abstract][Full Text] [Related]
20. MCM6 indicates adverse tumor features and poor outcomes and promotes G1/S cell cycle progression in neuroblastoma.
Gu Y; Hu X; Liu X; Cheng C; Chen K; Wu Y; Wu Z
BMC Cancer; 2021 Jul; 21(1):784. PubMed ID: 34233647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
